Augmenting nab-paclitaxel/gemcitabine standard chemotherapy response by merestinib, an inhibitor of c-MET, Axl and DDR signaling pathways, in preclinical pancreatic cancer models
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.